login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

FDA clears first ever bi-directionally retrievable vena cava filter from Crux Biomedical


Thursday, 19 Jul 2012 11:17
Tom Fogarty
Tom Fogarty


The US Food and Drug Administration (FDA) has cleared Crux Biomedical’s inferior vena cava filter with bi-directional retrieval for the prevention of pulmonary embolism. This feature allows retrieval of the device from the femoral or jugular veins, a key consideration when access to one or the other vein is limited.


“Crux designed a device that is both more versatile and simple to use,” said Tom Fogarty, cardiovascular surgeon and founder of Crux Biomedical. “Bi-directional deployment and retrieval are extremely helpful in situations where access to either the femoral or jugular vein is not possible. The Crux vena cava filter with its innovative design and materials represents a paradigm shift in prevention of pulmonary embolisms in patients at risk.”

A recently completed pivotal trial consisting of 125 patients at high risk for pulmonary embolisms, called the RETRIEVEclinical study, was performed at 22 sites in the USA, Australia, New Zealand and Belgium. The study results were presented at the 2012 Society for Interventional Radiology (SIR) meeting.


In the study, the technical success rate of filter deployment was 98%; filter retrieval success was also 98%. The average retrieval time was 7 minutes. By the 6-month follow up of the study, no embolizations, migrations or fractures were observed.


“The Crux device demonstrated excellent deployment, retrieval and safety profile,” stated Robert R Mendes, principal investigator of the study; associate professor of Surgery, University of North Carolina; and Chief of Vascular Surgery, Rex UNC Healthcare. “The clinical study evaluation has demonstrated the Crux vena cava filter can be used safely for the prevention of recurrent pulmonary embolisms.”


“The Crux vena cava filter system is the first major design innovation in vena cava filters in some 40 years,” said Mel Schatz, CEO, Crux Biomedical. “We have been pleased with both the clinical outcomes in our pivotal clinical trial and the enthusiasm expressed by physicians using the Crux vena cava filter.” The device’s novel helical shape was designed to self-center and to conform more closely to the shape of the vena cava, as well as to reduce bends and stress that can compromise filter integrity.




Add New Comment

Related Items


Most popular


Ultrasound-guided radiofrequency ablation results in significant volume reduction for benign thyroid nodules
Friday, 04 Mar 2016
Two studies presented at the European Congress of Radiology (2–6 March, Vienna, Austria) have found that radiofrequency ablation could have a role in the treatment of thyroid nodules. Ultrasound-guided radiofrequency ablation results in significant volume reduction for benign thyroid nodules

Monday, 14 Mar 2016
Although systemic thrombolysis achieves similar rates of mortality as catheter-directed intervention for the treatment of acute pulmonary embolism, it also carries “significantly increased odds of ... Systemic thrombolysis for acute pulmonary embolism increases stroke risk compared with catheter-directed intervention

Silk Road Medical receives CE mark for next-generation Enroute transcarotid neuroprotection system
Wednesday, 16 Mar 2016
Silk Road Medical has been granted CE approval for its Enroute transcarotid neuroprotection system (NPS). The company has also reported the first patients have been treated with the system. Silk Road Medical receives CE mark for next-generation Enroute transcarotid neuroprotection system

Features


A research track record helps physicians assess new technology
Tuesday, 12 Apr 2016
Scott Trerotola, Stanley Baum Professor and chief, Vascular and Interventional Radiology, University of Pennsylvania Medical Center, Philadelphia, USA, delivered the Dr Charles T Dotter Lecture at ... A research track record helps physicians assess new technology

How we innovate must change dramatically
Friday, 01 Apr 2016
In order to fully capitalise on the potential of advances in materials, drugs, biologics, sensing, informatics, guidance, manufacturing processes and marketing, an organised collaborative approach to ... How we innovate must change dramatically

Profiles


Gabriel Bartal
Thursday, 26 Nov 2015
“In the early days, I used to have to cut a 7F plastic tube, make side holes, send it off for ... Gabriel Bartal

Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions